VEGFA and neoplasm: Despite significant depletion of VEGFR-2+/CD31+ tumor endothelial cells, SLT-VEGF treatment did not affect the growth of primary tumors (Figure 4), suggesting that in our model such cells do not play a critical role in maintaining angiogenesis once tumors have achieved a certain growth threshold.